Royal Bank of Canada’s Phathom Pharmaceuticals PHAT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.52M | Buy |
157,941
+147,759
| +1,451% | +$1.42M | ﹤0.01% | 3247 |
|
|
2025
Q1 | $64K | Sell |
10,182
-1,405
| -12% | -$8.83K | ﹤0.01% | 5094 |
|
|
2024
Q4 | $94K | Buy |
11,587
+4,581
| +65% | +$37.2K | ﹤0.01% | 4913 |
|
|
2024
Q3 | $126K | Buy |
7,006
+2,753
| +65% | +$49.5K | ﹤0.01% | 4739 |
|
|
2024
Q2 | $44K | Buy |
4,253
+2,237
| +111% | +$23.1K | ﹤0.01% | 5330 |
|
|
2024
Q1 | $22K | Sell |
2,016
-8,416
| -81% | -$91.8K | ﹤0.01% | 5436 |
|
|
2023
Q4 | $94K | Buy |
10,432
+4,716
| +83% | +$42.5K | ﹤0.01% | 5129 |
|
|
2023
Q3 | $59K | Buy |
5,716
+3,214
| +128% | +$33.2K | ﹤0.01% | 5213 |
|
|
2023
Q2 | $36K | Buy |
2,502
+617
| +33% | +$8.88K | ﹤0.01% | 5480 |
|
|
2023
Q1 | $13K | Sell |
1,885
-2,254
| -54% | -$15.5K | ﹤0.01% | 5815 |
|
|
2022
Q4 | $46K | Buy |
4,139
+3,859
| +1,378% | +$42.9K | ﹤0.01% | 5470 |
|
|
2022
Q3 | $3K | Buy |
280
+150
| +115% | +$1.61K | ﹤0.01% | 6420 |
|
|
2022
Q2 | $1K | Sell |
130
-1,114
| -90% | -$8.57K | ﹤0.01% | 6707 |
|
|
2022
Q1 | $17K | Sell |
1,244
-3,203
| -72% | -$43.8K | ﹤0.01% | 6206 |
|
|
2021
Q4 | $87K | Buy |
4,447
+2,579
| +138% | +$50.5K | ﹤0.01% | 5505 |
|
|
2021
Q3 | $60K | Buy |
1,868
+481
| +35% | +$15.5K | ﹤0.01% | 5539 |
|
|
2021
Q2 | $47K | Buy |
1,387
+725
| +110% | +$24.6K | ﹤0.01% | 5589 |
|
|
2021
Q1 | $25K | Buy |
+662
| New | +$25K | ﹤0.01% | 5804 |
|
|
2020
Q4 | – | Sell |
-7
| Closed | – | – | 6627 |
|
|
2020
Q3 | $0 | Sell |
7
-13
| -65% | – | ﹤0.01% | 6292 |
|
|
2020
Q2 | $1K | Sell |
20
-494
| -96% | -$24.7K | ﹤0.01% | 5987 |
|
|
2020
Q1 | $13K | Sell |
514
-179
| -26% | -$4.53K | ﹤0.01% | 5236 |
|
|
2019
Q4 | $22K | Buy |
+693
| New | +$22K | ﹤0.01% | 5219 |
|